Cervical cancer continues to represent an immense burden worldwide. Fortunately, in all stages of the disease and therapeutic modalities there have been significant advances in the past 5 years with the promise of improving oncologic outcomes and decreasing morbidity. The introduction of immunotherapy into the care of patients with metastatic and recurrent cervical cancer, a disease with a historically poor prognosis and limited treatment options, has altered the standard of care.